Bacterin announces publication of OsteoSponge clinical results Bacterin announced that results utilizing OsteoSponge bone graft for foot and ankle arthrodeses procedures has been published in the peer-reviewed journal Orthopedics. The article reports a prospective analysis of 25 patients who underwent foot and ankle arthrodesis involving 45 total joints. Results indicated that 96% of patients showed radiographic fusion at 6 and 12 months postoperative assessment, with a 97.4% overall fusion rate. Pain was assessed pre and postoperatively via visual analog scale, with statistically significant improvements at 6 and 12 months relative to preoperative pain scores. Functional outcomes were significantly improved at 6 and 12 months compared with preoperative assessment according to American Orthopaedic Foot and Ankle Society scores.
NYSE MKT to commence delisting proceedings against Bacterin NYSE MKT announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Bacterin International Holdings - ticker symbol BONE - from NYSE MKT.